Analysts at JPMorgan Chase & Co. published research on July 3, 2026, identifying Block, Inc. and Lantheus Holdings as two Strong Buy equity ideas for the remainder of the year. The firm’s price targets imply significant potential upside, underscoring a high-conviction stance on these specific names. The announcement was made as JPMorgan’s own stock traded at $334.47, up 2.18% on the day. This selective optimism arrives during a period of heightened market scrutiny on earnings sustainability and valuation.
Context — [why this matters now]
JPMorgan’s research arm is one of the most influential voices for institutional capital allocation, making its high-conviction calls closely watched for directional signals. The last major thematic pivot from the firm occurred in Q1 2025, when it shifted its overweight stance from mega-cap tech to energy infrastructure. The current macroeconomic backdrop features the S&P 500 trading near all-time highs amidst persistent questions about the trajectory of interest rates and consumer spending.
The catalyst for these specific recommendations appears to be a combination of company-specific catalysts and attractive relative valuation. For Block, the focus is on the potential for margin expansion within its Cash App and Square ecosystems as operating efficiencies improve. For Lantheus, a leader in radiopharmaceuticals, the driver is the anticipated growth in diagnostic and therapeutic oncology products. This bifurcated approach suggests JPMorgan is seeking alpha in both disruptive fintech and specialized healthcare, sectors with different underlying economic drivers.
Data — [what the numbers show]
JPMorgan’s analysis assigns explicit price targets that define the projected upside for each stock. For Block, Inc. (SQ), the firm set a price target that implies an approximate 42% increase from recent trading levels. For Lantheus Holdings (LNTH), the target suggests potential gains exceeding 45%. These targets are substantially above the consensus analyst price targets for both companies, indicating a more bullish stance than the broader Wall Street view.
JPMorgan’s own shares have demonstrated strength, trading in a range between $331.88 and $338.84 during the session and settling at $334.47 as of 16:59 UTC today. This 2.18% daily gain for JPM outperformed the financial sector ETF (XLF), which was up only 0.8% on the same day. The significant gap between JPMorgan's targets and current prices highlights a distinct valuation opportunity the firm's analysts have identified.
| Metric | Block, Inc. (SQ) | Lantheus Holdings (LNTH) |
|---|
| JPMorgan Rating | Strong Buy | Strong Buy |
| Implied Upside | ~42% | ~45% |
| Sector | Financial Services / Technology | Healthcare / Radiopharma |
Analysis — [what it means for markets / sectors / tickers]
The dual Strong Buy ratings signal a tactical rotation into names with clear, near-term earnings catalysts rather than broad sector bets. Positive sentiment around Block could provide a tailwind for other fintech and payment processors like PayPal (PYPL) and Shift4 (FOUR), as it validates growth narratives in digital payments. Strength in Lantheus may buoy the broader radiopharmaceutical sector, including companies like Perspective Therapeutics (CATX).
A key risk to this thesis is macroeconomic sensitivity. Block’s seller ecosystem is tied to small business health, which could weaken in an economic downturn, while Lantheus’s growth is partially dependent on stable healthcare reimbursement policies. Institutional flow data suggests hedge funds have been underweight both names, indicating the potential for significant short covering if the stocks begin to appreciate, which would accelerate upward price movement. The call represents a vote of confidence in these companies' abilities to execute independently of macro headwinds.
Outlook — [what to watch next]
The immediate catalyst for both stocks will be their Q2 2026 earnings reports, expected in early August. For Block, investors will scrutinize gross profit growth for the Cash App and Square segments, with a focus on guiding toward sustained double-digit expansion. For Lantheus, key metrics will include sales growth for its Pluvicto and Pylarify products and updates on its diagnostic pipeline.
Technically, SQ shares need to hold support above the 50-day moving average near $68 to maintain a bullish near-term structure. For LNTH, a sustained break above $120 would confirm the bullish momentum suggested by JPMorgan’s upgrade. Beyond earnings, regulatory announcements from the Centers for Medicare & Medicaid Services regarding drug reimbursement rates in Q4 will be critical for Lantheus’s long-term profitability. The performance of these two stocks will serve as a barometer for investor appetite for high-growth, high-conviction ideas through the second half of the year.
Frequently Asked Questions
What is a Strong Buy rating from JPMorgan?
A Strong Buy rating is the highest conviction recommendation issued by JPMorgan’s equity research team. It signifies the analysts believe the stock’s potential for appreciation significantly outweighs the risks and that it is expected to outperform the broader market and its sector peers over a defined period, typically 6-12 months. This rating is reserved for situations where the analysts’ fundamental analysis points to a high probability of the stock reaching its price target.
How does JPMorgan's price target for Block compare to other analysts?
JPMorgan’s price target for Block is notably above the current consensus price target among Wall Street analysts. The consensus view often represents an average of dozens of analyst estimates, which can be influenced by a range of opinions. JPMorgan’s高出共识的目标表明，其分析团队对Block实现更高盈利的能力比同行更具信心，可能是基于专有数据或更乐观的扩张假设。
Why would a bank recommend stocks other than its own?
Investment banking divisions and equity research departments at major firms like JPMorgan operate with strict information barriers, known as Chinese walls, to prevent conflicts of interest. The equity research team’s primary duty is to provide independent analysis to institutional asset management clients. Their compensation is tied to the accuracy and insight of their research, not the performance of the bank’s own stock or banking fees from the companies they cover.
Bottom Line
JPMorgan is betting on Block and Lantheus to deliver outlier returns based on company-specific execution, not macro trends.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
